Save Product
Product Details
Background
Recombinant Monoclonal Anti-CD19 Antibody, Rabbit (4A6) is a CD19 primary antibody for IHC application. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge.
Product Specifications
Host SpeciesRabbitIsotypeRabbit IgG, Rabbit KappaClone4A6ApplicationIHC-PDilution Ratio1: 500 - 1: 2000FormLiquidClonalityMonoclonalReactivityHumanSynonymsLeu-12Concentration0.9~1.1 mg/mlSpecificityReact with CD19 protein on the membrane of target cell/tissuePurification TechProtein APreservationPBS, BSA, GlycerolExperiment Protocol
Storage
Shipped at 4°C, Blue Ice. Store at +4°C for short term (1-2 weeks). Store at -20°C for long term.
Avoid freeze / thaw cycle. Upon delivery aliquot. The shelf life is 30 days from the date of opening.ACRO Quality Management System
Customers Also Viewed
Performance Data
Sample Staining Data
Immunohistochemical analysis of paraffin embedded human cancer tissue labelled with HGS-S259 at 1/1000 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
B-lymphocyte antigen CD19
- Category：
- Approved Drugs：
14 Details
- Drugs in Clinical Trials：
435 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
